Healthcare Services

Omics-Based Clinical Trials Market Forecast 2026–2035: Data Trends and Industry Insights

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the omics-based clinical trials market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Omics-Based Clinical Trials Market by the end of 2030?

The omics-based clinical trials market has experienced significant expansion in recent years. Forecasts indicate it will advance from $31.71 billion in 2025 to $34.49 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. This historical growth is attributable to several key factors, including the increasing complexity of clinical trial designs, progress in genomic and proteomic research, a heightened demand for personalized therapies, the enlargement of clinical research infrastructure, and enhanced collaboration between pharmaceutical and academic institutions.

The market for omics-based clinical trials is projected to experience robust expansion over the coming years. This market is anticipated to reach $47.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This projected growth is driven by factors such as the increasing embrace of precision medicine, greater investments in clinical trials relying on data, the broader application of AI in patient recruitment, a rise in regulatory approval for omics-based endpoints, and a heightened need for effective trial results. Key developments expected during this forecast period encompass a greater prevalence of trial designs guided by biomarkers, expanded utilization of multi-omics for patient stratification, enhanced incorporation of real-world evidence analytics, an increase in precision oncology clinical trials, and a stronger emphasis on optimizing trials through data.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp

What Drivers Are Shaping Future Opportunities In The Omics-Based Clinical Trials Market?

The anticipated expansion of the omics-based clinical trials market is driven by the growing need for personalized medicine. This medical strategy customizes disease prevention, diagnosis, and treatment according to each patient’s unique characteristics. The increasing adoption of personalized medicine stems from progress in genomic technologies, which facilitate quicker and more economical analysis of individual genetic profiles to inform specific therapies. Omics-based clinical trials contribute to personalized medicine by enabling the identification of unique genetic, proteomic, and metabolic profiles, thus leading to more precise and efficacious treatment plans customized for each patient. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, reported that the US Food and Drug Administration sanctioned 16 novel personalized treatments for rare disease patients in 2023. This marks an increase from six approvals in 2022, with the 2023 approvals additionally covering seven oncology therapies and three treatments for various other ailments. Consequently, the expanding need for personalized medicine is fueling the growth of the omics-based clinical trials market.

Which Segment Groups Are Influencing The Omics-Based Clinical Trials Market?

The omics-based clinical trials market covered in this report is segmented –

1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics

2) By Phase: Phase I, Phase II, Phase III, Phase IV

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders

5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories

Subsegments:

1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing

2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping

3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis

4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

Which Innovation Trends Are Advancing Developments Within The Omics-Based Clinical Trials Market?

Leading companies in the omics-based clinical trials market are prioritizing innovative solutions, such as HiFi sequencing technology, to improve the accuracy, speed, and depth of multi-omics data analysis, ultimately enhancing trial outcomes and personalized treatment strategies. HiFi sequencing is a next-generation sequencing (NGS) technology that produces long, highly accurate reads through circular consensus sequencing (CCS), facilitating comprehensive and precise analysis of genomes, transcriptomes, and epigenomes. For instance, in October 2024, Pacific Biosciences of California Inc., a US-based biotechnology company, collaborated with the Agency for Science, Technology, and Research (A*STAR), a Singapore-based research and product development agency, and Macrogen Inc., a South Korea-based biotechnology company, to establish a state-of-the-art lab aimed at accelerating genomics innovation in Singapore using cutting-edge long-read sequencing technology. This facility allows researchers to perform advanced genomic studies with enhanced precision and speed. It supports a broad spectrum of applications, including whole genome sequencing, transcriptomics, epigenetics, and metagenomics. The lab also encourages collaboration among global scientists and local institutions, intending to accelerate discoveries in personalized medicine, rare disease diagnostics, and precision oncology. Additionally, it provides training programs and shared access to high-throughput sequencing infrastructure, fostering capacity-building and innovation throughout the Asia-Pacific region.

Who Are The Core Companies Influencing Trends In The Omics-Based Clinical Trials Market?

Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Omics-Based Clinical Trials Market?

North America was the largest region in the omics-based clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Omics-Based Clinical Trials Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp

Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2026, By The Business Research Company

Polymer Coated Fabrics Market Report 2026

https://www.thebusinessresearchcompany.com/report/polymer-coated-fabrics-global-market-report

Asphalt Additives Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report

Asphalt Pavers Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795